AUTL Stock Analysis: Buy, Sell, or Hold?
AUTL - Autolus Therapeutics plc American Depositary Share
$1.61
-0.08 (-4.73%)
▼
5d:
+1.9%
30d:
+10.27%
90d:
+9.52%
BUY
MODERATE Confidence
Analysis Updated: Jul 10, 2026 12:00 AM ET
Earnings: Aug 11, 2026
30d
Get Alerted When AUTL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: AUTL shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: AUTL shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: AUTL is currently trading at $1.61, which is considered fair relative to its 30-day fair value range of $1.50 to $1.68.
Technical Outlook: Technically, AUTL is showing sideways momentum. Immediate support is located at $1.54, while resistance sits at $1.75. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.55 (+431.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AUTL is showing sideways momentum. Immediate support is located at $1.54, while resistance sits at $1.75. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.55 (+431.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.50 -
$1.68
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.7%)
- BULLISH: Trading 431.1% below Wall St target ($8.55)
Trading Range Analysis
30-Day Trading Range
$1.50 -
$1.68
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.54
Resistance Level
$1.75
Current Trend
Sideways
Technical data as of
Jul 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.68
Wall Street Target
$8.55
(+431.1%)
Revenue Growth (YoY)
83655.2%
Share & Embed Analysis
Last updated: July 11, 2026 2:46 AM ET
Data refreshes hourly during market hours. Next update: 3:46 AM
Data refreshes hourly during market hours. Next update: 3:46 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AUTL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 57 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 62 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 56 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 63 BUY |
